Multiple Myeloma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Sox11 was then examined in plasma cell myeloma and hairy cell leukemia as a subset of plasma cell myeloma carry t(11;14) and overexpress cyclin D1, and cyclin D1 is overexpressed in a subset of hairy cell leukemia independent of t(11;14).
|
19801969 |
2010 |
Multiple Myeloma
|
0.700 |
Biomarker
|
disease |
BEFREE |
To test the tumorigenic potential of cyclin D1b in vivo, we generated cell clones derived from the non-CCND1 expressing MM LP-1 cell line, synthesizing either cyclin D1b or cyclin K, a structural homolog and viral oncogenic form of cyclin D1a.
|
20459741 |
2010 |
Multiple Myeloma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Moreover, H3K9 acetylation at c-myc and CCND1 promoters was increased in individual MM patients after melphalan treatment.
|
19362368 |
2009 |
Multiple Myeloma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Ectopic cyclin D1 overexpression increases chemosensitivity but not cell proliferation in multiple myeloma.
|
19020753 |
2008 |
Multiple Myeloma
|
0.700 |
Biomarker
|
disease |
BEFREE |
We therefore quantified levels of total and Delta3'UTR cyclin D1 mRNA by real-time RT-PCR in cytogenetically characterized cyclin D1+MM primary cases, and cyclin D1+cell lines.
|
17629555 |
2008 |
Multiple Myeloma
|
0.700 |
GeneticVariation
|
disease |
LHGDN |
In contrast, double-color fluorescence in situ hybridization analysis showed that BM-derived CD138-positive myeloma cells possessed the gene translocation between the immunoglobulin heavy chain gene and the cyclin D1 gene, which was not involved in non-myeloma hematopoietic cells.
|
19129688 |
2008 |
Multiple Myeloma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
In mantle cell lymphoma (MCL) and some cases of multiple myeloma (MM), cyclin D1 expression is deregulated by chromosome translocations involving the immunoglobulin heavy chain (IgH) locus.
|
18625744 |
2008 |
Multiple Myeloma
|
0.700 |
Biomarker
|
disease |
BEFREE |
14q32 (IgH) translocations are highly prevalent in both sPCL and pPCL (82-87%); in pPCL IgH translocations almost exclusively involve 11q13 (CCND1), supporting a central etiological role, while in sPCL multiple partner oncogenes are involved, including 11q13, 4p16 (FGFR3/MMSET) and 16q23 (MAF), recapitulating MM.
|
18216867 |
2008 |
Multiple Myeloma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Close relation between 14q32/IGH translocations and chromosome 13 abnormalities in multiple myeloma: a high incidence of 11q13/CCND1 and 16q23/MAF.
|
18274833 |
2008 |
Multiple Myeloma
|
0.700 |
AlteredExpression
|
disease |
LHGDN |
Therefore, we assume that high sensitivity to anti-myeloma drugs depends on the duration of the S-phase, but a clinical response might depend on the number of myeloma cells with cyclin D1 overexpression.
|
19020753 |
2008 |
Multiple Myeloma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
JAK2V617F-positive essential thrombocythemia and multiple myeloma with IGH/CCND1 gene translocation coexist, but originate from separate clones.
|
19129688 |
2008 |
Multiple Myeloma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
In this study, the prognostic significance of morphology, CyclinD1 expression, proliferation index (Mib1) and presence of the translocations FGFR3/IgH [t(4;14)] and CCND1/IgH [t(11;14)] are compared in 119 patients with PM.
|
17460451 |
2007 |
Multiple Myeloma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Cyclin D1 is detectable in up to one third of MM patients and plays crucial role in the regulation of G1-S transition in cell cycle.
|
17284370 |
2007 |
Multiple Myeloma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Simultaneous translocations of FGFR3/MMSET and CCND1 into two different IGH alleles in multiple myeloma: lack of concurrent activation of both proto-oncogenes.
|
17498561 |
2007 |
Multiple Myeloma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
To address the effects of cyclin D1 overexpression might have on the response of malignant hematopoietic cells to CDK inhibitors, the impact of ectopic cyclin D1 overexpression on the response of human multiple myeloma U266 cells to various cyclin-dependent kinase (CDK) inhibitors was examined.
|
16479154 |
2006 |
Multiple Myeloma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Cyclin D1 mRNA isoforms a and b were expressed in mantle cell lymphoma (MCL) and multiple myeloma (MM).
|
17022831 |
2006 |
Multiple Myeloma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Immunohistochemical analysis identifies two cyclin D1+ subsets of plasma cell myeloma, each associated with favorable survival.
|
16627271 |
2006 |
Multiple Myeloma
|
0.700 |
AlteredExpression
|
disease |
LHGDN |
Cyclin D1 mRNA isoforms a and b were expressed in mantle cell lymphoma (MCL) and multiple myeloma (MM).
|
17022831 |
2006 |
Multiple Myeloma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Our results show that this region is not methylated in 6 human MM cell lines as well as in normal B lymphocytes, independently of cyclin D1 expression.
|
15911089 |
2005 |
Multiple Myeloma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Molecular classification of multiple myeloma: a distinct transcriptional profile characterizes patients expressing CCND1 and negative for 14q32 translocations.
|
16129847 |
2005 |
Multiple Myeloma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Furthermore, gene expression profiling enabled the identification of putative translocations causing dysregulation of CCND1 (1 MM and 1 PCL) and MAFB (1 MM and 1 PCL) without any apparent involvement of immunoglobulin loci.
|
15543617 |
2005 |
Multiple Myeloma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Virtually all MM and MGUS tumors have dysregulated and/or increased expression of cyclin D1, D2, or D3, providing an apparent early, unifying event in pathogenesis.
|
16155016 |
2005 |
Multiple Myeloma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Cyclin D1, D2, or D3 expression appears to be increased and/or dysregulated in virtually all MM tumors despite their low proliferative capacity.
|
15755896 |
2005 |
Multiple Myeloma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Our data indicate that deregulation of MYEOV is not favored in MM and further strengthens the role of cyclin D1 overexpression in lymphoid malignancies with a t(11;14)(q13;q32) translocation.
|
15090460 |
2004 |
Multiple Myeloma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Nearly half of these tumors are nonhyperdiploid and mostly have immunoglobulin H (IgH) translocations that involve 5 recurrent chromosomal loci, including 11q13 (cyclin D1), 6p21 (cyclin D3), 4p16 (fibroblast growth factor receptor 3 [FGFR3] and multiple myeloma SET domain [MMSET]), 16q23 (c-maf), and 20q11 (mafB).
|
15090448 |
2004 |